14th Oct 2014 09:11
LONDON (Alliance News) - Cyprotex PLC said Tuesday that it has launched an improved version of its SenCeeTox technology, a model used to predict 'in vitro' skin sensation.
Cyprotex acquired the technology with CeeTox Inc in January. It is an in vitro model that uses multiple endpoints to predict skin sensation.
In the EU there is a ban on animal testing of cosmetics, personal care ingredients and finished products, which has driven a need to develop alternative in vitro methods. An in vitro study is performed on cells or molecules outside of their normal biological context.
"This improved SenCeeTox approach provides a robust and accurate method for assessing skin sensitisation potential which is superior to existing methods currently recommended by the regulatory authorities," said Chief Executive Anthony Baxter in a statement.
Shares in Cyprotex are trading down 2.2% at 44.00 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L